Physician profile
Jon Stauffer
NPI 1194720177
$6,733.94
in general payments reported to CMS, 2019-2025
23 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,809 · 2020: $961 · 2021: $466 · 2022: $402 · 2023: $317 · 2024: $1,403 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,095.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,024.04 | 2019-2025 | Linzess, Viberzi, Creon |
| Covidien Lp | $1,131.78 | 2019-2020 | |
| Janssen Biotech, INC. | $946.42 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Boston Scientific Corporation | $550.69 | 2019-2023 | Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $464.46 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $326.26 | 2019-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $186.85 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $182.67 | 2024-2025 | Dupixent |
| Gilead Sciences, INC. | $149.02 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $140.72 | 2020-2025 | |
| Ironwood Pharmaceuticals, INC | $103.21 | 2019-2024 | Linzess |
| Ardelyx, INC. | $85.96 | 2023-2025 | Ibsrela |
| Pfizer INC. | $84.84 | 2020-2022 | |
| Allergan, INC. | $67.19 | 2019-2020 | |
| Organon LLC | $51.34 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $49.89 | 2019 | |
| Daiichi Sankyo INC. | $49.71 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $46.51 | 2024-2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $30.11 | 2021-2024 | Rebyota |
| Celgene Corporation | $16.71 | 2024 | Zeposia |
| Qol Medical, LLC | $16.67 | 2023 | Sucraid |
| Olympus America INC. | $15.37 | 2021 | |
| Medtronic, INC. | $13.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Stauffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.